Report : Europe Malaria Treatment Market Forecast to 2027 - COVID-19 Impact and Regional Analysis By Treatment Type (Antimalarial Agents, and Diagnostic Test); Route of Administration (Oral, and Parenteral); End User (Hospitals, Specialty Clinics, and Others)
At 4.8% CAGR, the Europe Malaria Treatment Market is speculated to be worth US$ 785.75 million by 2028, says Business Market Insights
According to Business Market Insights’ research, the Europe malaria treatment market was valued at US$ 593.03 million in 2022 and is expected to reach US$ 785.75 million by 2028, registering a CAGR of 4.8% from 2022 to 2028. Extending pipeline of new drugs and vaccines and rapid diagnostic tests are the critical factors attributed to the Europe malaria treatment market expansion.
RDTs for malaria can improve the quality of management of the disease. RDTs are proven to be highly affordable and effective for public health programs implemented in low-resource settings. RDTs are widely used in remote areas with limited access to microscopy services. As a result, there has been a rapid rise in the demand for RDTs for malaria. Several RDTs have been developed to test the presence of malaria parasites in blood samples. Identifying and successfully treating malaria in low transmission areas is critical to reduce transmission and achieve complete elimination of the disease. Many companies are engaged in developing a wide range of RDTs with high sensitivities. A few of these developments have taken place in recent years. So, growing rapid diagnostic tests is expected to drive the Europe malaria treatment market.
On the contrary, counterfeit antimalarial drugs and subsequent drug resistance hurdles the growth of Europe malaria treatment market.
Based on treatment, the Europe malaria treatment market is segmented into prescription medications, vaccines, diagnostic tests, and others. The diagnostic tests segment held 44.1% market share in 2022, amassing US$ 261.56 million. It is projected to garner US$ 340.94 million by 2028 to expand at 4.5% CAGR during 2022–2028. Further, prescription medications segment is further categorized into chloroquine phosphate, artemisinin-based combination therapies (ACTs), atovaquone-proguanil, quinine sulfate (qualaquin) with doxycycline, primaquine phosphate, and others.
Based on drug type, the Europe malaria treatment market is bifurcated into branded and generic. The generic segment held 63.2% market share in 2022, amassing US$ 374.85 million. It is projected to garner US$ 485.45 million by 2028 to expand at 4.4% CAGR during 2022–2028.
Based on route of administration, the Europe malaria treatment market is bifurcated into oral and parenteral & intravenous. The oral segment held 71.4% market share in 2022, amassing US$ 423.51 million. It is projected to garner US$ 555.53 million by 2028 to expand at 4.6% CAGR during 2022–2028.
Based on distribution channel, the Europe malaria treatment market is segmented into direct tender, hospital pharmacies, retail pharmacies, online pharmacies, and others. The direct tender segment held 45.3% market share in 2022, amassing US$ 268.41 million. It is projected to garner US$ 356.80 million by 2028 to expand at 4.9% CAGR during 2022–2028.
Based on end user, the Europe malaria treatment market is segmented into hospitals, specialty clinics, homecare, and others. The hospitals segment held 46.0% market share in 2022, amassing US$ 272.91 million. It is projected to garner US$ 350.38 million by 2028 to expand at 4.3% CAGR during 2022–2028.
Based on country, the Europe malaria treatment market has been categorized into the UK, Germany, France, Italy, Spain, and the Rest of Europe. Our regional analysis states that Germany captured 29.5% market share in 2022. It was assessed at US$ 174.65 million in 2022 and is likely to hit US$ 226.22 million by 2028, exhibiting a CAGR of 4.4% during the forecast period.
Key players dominating the Europe malaria treatment market are AdvaCare Pharma USA LLC, Cipla Ltd, GSK Plc, Lupin Ltd, Novartis AG, Sanofi SA, Sun Pharmaceutical Industries Ltd, Viatris Inc, and Zydus Healthcare Ltd, among others.
- In Sep 2022, GSK plc announced that the World Health Organization (WHO) has awarded prequalification to Mosquirix (also known as RTS,S/AS01), GSK’s groundbreaking malaria vaccine. This is the first prequalification for a malaria vaccine and is an important step in rolling out the vaccine in countries with moderate to high P. falciparum malaria transmission
- In July 2020, Novartis advanced another novel malaria therapy, INE963, a fast-acting long-lasting antimalarial with an entirely new mechanism of action. INE963 is in early clinical trials. It was developed in collaboration with MMV and received the organization’s “Project of the Year” award in 2020.
Contact Person: Sameer Joshi
Phone: +1- 646- 491- 9876
Email id: email@example.com